IPS Therapeutique (IPST)

IPS Therapeutique (IPST) is a Contract Research Organization dedicated to the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models. At IPST we believe each study is worthy of tailored protocols designed to maximize the scientific and strategic value of the data generated. We believe in taking ownership of the studies entrusted to IPST while ensuring mutual collaboration for developing and agreeing to overall project plans. Established in 1999, we have conducted more than 3,000 preclinical cardiac safety and efficacy studies and over 120 GLP-compliant studies in support of FDA, EMEA, Health Canada...

Cardiometabolic studies,cardiovascular safety studies,respiratory studies,bleeding disorders studies,functional fibrinogen assay,action potential kinetics,herg inhibition assay,ischemia reperfusion models,monocrotaline-induced pah models,chronic hypoxia models,liver fibrosis models,plasma protein binding assays,medication-induced heart failure models,type 2 diabetes models,liver fibrosis models,acute hypoxia models,copd models,ipf,hfpef,hfref,nash,pah,ards,mi,and silicosis

Ips therapeutique (ipst) operates in the Biotechnology research industry.

Ips therapeutique (ipst)'s revenue is 11m - 100m

Ips therapeutique (ipst) has 11 - 50 employees.